Crawford Resigns; NCI Director Von Eschenbach Named To Top FDA Spot

Related Content

Sweeping Changes At CDER Recommended In IoM Drug Safety Report

No Double Duty For Von Eschenbach; Niederhuber To Run NCI

FDA’s Plan B Decision To Be Guided By Public Comments, Deputy Commissioner Says

FDA Cancels Series Of Town Hall Meetings Following Commissioner Crawford’s Resignation

FDA Stresses Stability Following Commissioner Crawford's Resignation

FDA Women’s Health Director Resigns Over Plan B

Follow-On Biologics White Paper From FDA Could Be Delayed Until Fall

Follow-On Biologics White Paper From FDA Could Be Delayed Until Fall

Drug Safety Director Post To Be Filled By Late September, FDA’s Crawford Says

Crawford Nomination To Be FDA Commissioner Clears Senate 78-16